TESTOSTERONE REPLACEMENT THERAPY IN MEN WITH HYPOGONADISM AND CARDIOVASCULAR RISK: A SYSTEMATIC REVIEW

• DOI: https://doi.org/10.22533/at.ed.1594752412086

• Palavras-chave: Hypogonadism; Testosterone; Hormone Replacement Therapy; Heart Disease Risk Factors.

• Keywords: Hypogonadism; Testosterone; Hormone Replacement Therapy; Heart Disease Risk Factors.

• Abstract:

  Evidence on the relationship between hormone replacement therapy in men with hypogonadism and cardiovascular risk is controversial. We sought to evaluate the effects of hormone replacement therapy on cardiovascular risk in men with hypogonadism. For this systematic review, we used the search tools PubMed, SCIELO, The Lancet and The New England Journal of Medicine for studies published in the databases with emphasis on 2018 and onwards, both in Portuguese and English. The descriptors used were: Hypogonadism, Testosterone, Hormone Replacement Therapy, Heart Disease Risk Factors, Testosterone, Hypogonadism, cardiovascular risk. More than 50 thousand articles were found, of which 1,682 were related to the topic, and 33 were selected and analyzed. Given the above, the scientific stigma of TRT increasing the incidence of negative cardiovascular outcomes gradually tends to be replaced by the perspective of cardioprotection and secondary benefits being promoted by TRT. It is concluded that hormone replacement therapy may offer cardioprotective benefits, as evidenced by most studies analyzed from 2022 onwards.